Piceatannol improved cerebral blood flow and attenuated JNK3 and mitochondrial apoptotic pathway in a global ischemic model to produce neuroprotection
- PMID: 37470802
- DOI: 10.1007/s00210-023-02616-0
Piceatannol improved cerebral blood flow and attenuated JNK3 and mitochondrial apoptotic pathway in a global ischemic model to produce neuroprotection
Abstract
Cerebral ischemia is one of the leading causes of death and disability worldwide. The only FDA-approved treatment is recanalization with systemic tissue plasminogen activators like alteplase, although reperfusion caused by recanalization can result in neuroinflammation, which can cause brain cell apoptosis. Therefore, after an ischemic/reperfusion injury, interventions are needed to minimize the neuroinflammatory cascade. In the present study, piceatannol (PCT) was studied for its neuroprotective efficacy in a rat model of global ischemic injury by attenuating c-Jun N-terminal kinase 3 (JNK3) downstream signaling. PCT is a resveratrol analog and a polyphenolic stilbenoid naturally occurring in passion fruit and grapes. The neuroprotective efficacy of PCT (1, 5, 10 mg/kg) in ischemic conditions was assessed through pre- and post-treatment. Cerebral blood flow (CBF) and tests for functional recovery were assessed. Protein and gene expression were done for JNK3 and other inflammatory markers. A docking study was performed to identify the amino acid interaction. The results showed that PCT improved motor and memory function as measured by a functional recovery test believed to be due to an increase in cerebral blood flow. Also, the caspase signaling which promotes apoptosis was found to be down-regulated; however, nitric oxide synthase expression was up-regulated, which could explain the enhanced cerebral blood flow (CBF). According to our findings, PCT impeded c-Jun N-terminal kinase 3 (JNK3) signaling by suppressing phosphorylation and disrupting the mitochondrial apoptotic pathway, which resulted in the neuroprotective effect. Molecular docking analysis was performed to investigate the atomic-level interaction of JNK3 and PCT, which reveals that Met149, Leu206, and Lys93 amino acid residues are critical for the interaction of PCT and JNK3. According to our current research, JNK3 downstream signaling and the mitochondrial apoptosis pathway are both inhibited by PCT, which results in neuroprotection under conditions of global brain ischemia. Piceatannol attenuated JNK3 phosphorylation during the ischemic condition and prevented neuronal apoptosis.
Keywords: CBF; Cerebral ischemia; Global ischemia; PCT; SP6; c-Jun N-terminal kinase 3.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Piceatannol selectively inhibited the JNK3 enzyme and augmented apoptosis through inhibition of Bcl-2/Cyt-c/caspase-dependent pathways in the oxygen-glucose deprived SHSY-5Y cell lines: In silico and in vitro study.Chem Biol Drug Des. 2024 Feb;103(2):e14458. doi: 10.1111/cbdd.14458. Chem Biol Drug Des. 2024. PMID: 38383061
-
Neuroprotection of ethanol against ischemia/reperfusion-induced brain injury through decreasing c-Jun N-terminal kinase 3 (JNK3) activation by enhancing GABA release.Neuroscience. 2010 Jun 2;167(4):1125-37. doi: 10.1016/j.neuroscience.2010.02.018. Epub 2010 Feb 26. Neuroscience. 2010. PMID: 20219637
-
The potential role of HO-1 in regulating the MLK3-MKK7-JNK3 module scaffolded by JIP1 during cerebral ischemia/reperfusion in rats.Behav Brain Res. 2019 Feb 1;359:528-535. doi: 10.1016/j.bbr.2018.11.003. Epub 2018 Nov 6. Behav Brain Res. 2019. PMID: 30412737
-
Momordica charantia polysaccharides could protect against cerebral ischemia/reperfusion injury through inhibiting oxidative stress mediated c-Jun N-terminal kinase 3 signaling pathway.Neuropharmacology. 2015 Apr;91:123-34. doi: 10.1016/j.neuropharm.2014.11.020. Epub 2014 Dec 12. Neuropharmacology. 2015. PMID: 25510970
-
JNK3 inhibitors as promising pharmaceuticals with neuroprotective properties.Cell Adh Migr. 2024 Dec;18(1):1-11. doi: 10.1080/19336918.2024.2316576. Epub 2024 Feb 15. Cell Adh Migr. 2024. PMID: 38357988 Free PMC article. Review.
Cited by
-
Targeting Neurological Disorders with Stilbenes: Bridging the Preclinical-Clinical Gap.Int J Biol Sci. 2024 Oct 7;20(14):5474-5494. doi: 10.7150/ijbs.102032. eCollection 2024. Int J Biol Sci. 2024. PMID: 39494329 Free PMC article. Review.
-
Identification of potential JNK3 inhibitors through virtual screening, molecular docking and molecular dynamics simulation as therapeutics for Alzheimer's disease.Mol Divers. 2024 Dec;28(6):4361-4380. doi: 10.1007/s11030-024-10820-0. Epub 2024 Apr 4. Mol Divers. 2024. PMID: 38573427
References
-
- Abd El-Aal SA, Abd El-Fattah MA, El-Abhar HS (2017) CoQ10 augments rosuvastatin neuroprotective effect in a model of global ischemia via inhibition of NF-κB/JNK3/Bax and activation of Akt/FOXO3A/Bim cues. Front Pharmacol 8:735. https://doi.org/10.3389/fphar.2017.00735 - DOI - PubMed - PMC
-
- Akinwumi B, Bordun K-A, Anderson H (2018) Biological activities of stilbenoids. Int J Mol Sci 19(3):792. https://doi.org/10.3390/ijms19030792 - DOI - PubMed - PMC
-
- Al-Qazzaz N, Ali S, Ahmad SA, Islam S, Mohamad K (2014) Cognitive impairment and memory dysfunction after a stroke diagnosis: a post-stroke memory assessment. Neuropsychiatr Dis Treat, 1677. https://doi.org/10.2147/NDT.S67184
-
- Bastianetto S, Dumont Y, Han Y, Quirion R (2009) Comparative neuroprotective properties of stilbene and catechin analogs: action via a plasma membrane receptor site? CNS Neurosci Ther 15(1):76–83. https://doi.org/10.1111/j.1755-5949.2008.00074.x - DOI - PubMed - PMC
-
- Berger D, Varriale E, van Kessenich LM, Herrmann HJ, de Arcangelis L (2019) Three cooperative mechanisms required for recovery after brain damage. Sci Rep 9(1):15858. https://doi.org/10.1038/s41598-019-50946-y - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous